PubMed · 1985 · 166 citations · 35 references
MedicineNeurosciencePharmacologyBehavioral NeuroscienceNeuroendocrinologyNeuropharmacologyNeuromodulationNeuropeptide PharmacologyNeurotransmissionReward PathwaysCholecystokinin PharmacologyMesolimbic Reward Pathway
Cholecystokinin coexists with dopamine in mesolimbic neurons in mammalian brain. When injected directly into the nucleus accumbens, cholecystokinin (CCK) potentiated dopamine (DA)-induced hyperlocomotion and apomorphine-induced stereotypy. These effects were not mimicked by nonsulfated CCK, but were blocked by proglumide, a putative CCK antagonist, as well as by antisera raised against sulfated CCK. CCK alone had no effect on locomotion or sterotypy, indicating that this peptide acts primarily as a modulator of DA-mediated behaviors in the mesolimbic pathway. In addition, CCK did not potentiate DA-induced hyperlocomotion or apomorphine-induced stereotypy when injected into the caudate nucleus, where CCK and DA are localized in separate neurons in rats. Facilitation of DA-mediated behaviors by CCK may represent a functional interaction specific to the neuromodulator-neurotransmitter coexistence phenomenon.
35
Evidence for coexistence of dopamine and CCK in meso-limbic neurones
Tomas Hökfelt, Jens F. Rehfeld, L.R. Skirboll et al. · Nature · 1980 · 709 citations
Evidence for the Neuropeptide Cholecystokinin as an Antagonist of Opiate Analgesia
Patricia L. Faris, Barry R. Komisaruk, Linda R. Watkins et al. · Science · 1983 · 582 citations
Medicine, Neuroscience, Pharmacology +17